PycoClaw is a MicroPython-based platform for running AI agents on ESP32 and other microcontrollers that brings OpenClaw ...

JetBrains, the company behind the popular PyCharm IDE, offers a free introductory Python course. This is a pretty neat option if you like learning by doing, especially within a professional coding ...

The Contagious Interview campaign weaponizes job recruitment to target developers. Threat actors pose as recruiters from crypto and AI companies and deliver backdoors such as OtterCookie and ...

Imre Szenttornyay, CEO of Cielo IT LLC, empowers business owners to scale their operations profitably with AI-powered SmartSigns technology. When you manage a network of retail or franchise locations, ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

Getting ready for coding interviews can feel like a big task, and figuring out the best way to tackle LeetCode is a common question. Many people find that using Python for their LeetCode solutions ...

The Enhanced Reconsideration System (ERS) is a production-grade AI memory management library designed to transform stateless AI agents into stateful ones. It integrates asynchronous promise chains, ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...